title: Do we have to change the way targeted drugs are developed?
authors.forename: Alberto
authors.initials: A
authors.lastname: Ocana
authors.forename: Eitan
authors.initials: E
authors.lastname: Amir
authors.forename: Bostjan
authors.initials: B
authors.lastname: Seruga
authors.forename: Atanasio
authors.initials: A
authors.lastname: Pandiella
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt